FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:1673-1674 October 23, 2003 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Fasano, A. Related Article by Mäki, M. PubMed Citation

To the Editor: Despite the unexpectedly high prevalence of celiac disease found in the study by Mäki et al. (June 19 issue),¹ their use of endomysial and tissue transglutaminase antibodies as the sole serologic markers probably underestimated the prevalence of celiac disease in the cohort. One study evaluating endomysial antibodies showed that the sensitivity of this marker was 100 percent in patients with total villous atrophy, but the value plummeted to 31 percent in patients with celiac disease who had partial villous atrophy.² Antibodies to tissue transglutaminase likewise correlate with the degree of villous atrophy.³ Addition of the admittedly less . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.